PhotoBiotics, a med tech spin-out company from Imperial College London, recently closed a £390,000 funding round.
Investors include a number of London Business Angels Investors.
The company is developing innovative products for the treatment and diagnostic imaging of cancers, using biologically-targeted agents, denoted t-PDT, which should be both effective and avoid the side-effects seen with surgery, radiotherapy and chemotherapy.
The funding will support PhotoBiotics through 2010 in order to progress its R&D programme to achieve a significant value-adding milestone, taking the lead product candidate, ProstaLite for prostate cancer, to the point of entering formal preclinical development and subsequent Phase I/II clinical trials, as well as generating proof-of-concept in animals for an MRI imaging agent.
FinSMEs
11/05/2010